A 62-year-old man with diabetes mellitus is admitted with sepsis secondary to a hospital-acquired urinary tract infection. Urine culture yields a gram-negative rod resistant to ceftazidime, cefotaxime, and fluoroquinolones but susceptible to carbapenems and colistin. Which is the most common mechanism of resistance in this organism?

Explanation

## Extended-Spectrum Beta-Lactamase (ESBL): Most Common Mechanism in This Resistance Pattern ### Clinical Scenario Analysis **Key Point:** The resistance pattern—resistance to 3rd-generation cephalosporins (ceftazidime, cefotaxime) and fluoroquinolones with **preserved carbapenem susceptibility**—is the classic hallmark of **ESBL-producing** gram-negative organisms, most commonly *E. coli* and *Klebsiella pneumoniae* in hospital-acquired infections. ### Why ESBL is the Correct Answer 1. **Most common mechanism globally**: ESBL production (particularly CTX-M type) is the **most prevalent** resistance mechanism in gram-negative nosocomial pathogens worldwide, far exceeding AmpC in frequency. 2. **Cephalosporin resistance**: ESBLs hydrolyze all penicillins and 1st–3rd generation cephalosporins (including ceftazidime and cefotaxime). 3. **Carbapenem susceptibility**: ESBLs do NOT hydrolyze carbapenems — carbapenem susceptibility is preserved, which is a defining feature of ESBL (not carbapenemase) producers. 4. **Fluoroquinolone co-resistance**: ESBL-producing organisms frequently carry co-resistance to fluoroquinolones via plasmid-mediated mechanisms (e.g., *qnr* genes), consistent with this case. 5. **Clinical context**: Hospital-acquired UTI in a diabetic elderly patient is a classic ESBL scenario. ### Distinguishing ESBL from AmpC Beta-Lactamase | Feature | ESBL | AmpC Beta-Lactamase | |---------|------|--------------------| | **Cephalosporin resistance** | 3rd-gen (cefotaxime, ceftazidime) | 3rd-gen + cephamycins (cefoxitin) | | **Carbapenem susceptibility** | **Susceptible** | Susceptible (but may be resistant if combined with porin loss) | | **Inhibition by clavulanic acid** | Yes (inhibited) | No (not inhibited) | | **Common producers** | *E. coli*, *K. pneumoniae* | *Enterobacter*, *Citrobacter*, *Serratia* | | **Prevalence in nosocomial UTI** | **Most common** | Less common | | **Cefoxitin resistance** | Usually susceptible | Resistant (key differentiator) | **High-Yield:** The critical distinction between ESBL and AmpC is **cefoxitin (cephamycin) susceptibility**: ESBL producers are typically susceptible to cefoxitin, while AmpC producers are resistant. In this question, the absence of cefoxitin resistance and the classic 3rd-generation cephalosporin resistance pattern points to ESBL. ### Why Other Options Are Incorrect - **A) AmpC beta-lactamase**: AmpC producers (Enterobacter, Citrobacter, Serratia) characteristically resist cephamycins (cefoxitin) and are less commonly the cause of community-onset or hospital UTIs compared to ESBL-producing *E. coli/Klebsiella*. AmpC is not the most common mechanism in this clinical scenario. - **C) Reduced outer membrane permeability with efflux pump upregulation**: This mechanism contributes to resistance in *Pseudomonas aeruginosa* and *Acinetobacter*, but is not the most common mechanism in gram-negative nosocomial UTI pathogens. - **D) Altered penicillin-binding proteins (PBPs)**: This is the primary mechanism in MRSA and *Streptococcus pneumoniae*, not in gram-negative rods. **Clinical Pearl:** ESBL-producing organisms are susceptible to carbapenems (drug of choice), colistin, and sometimes fosfomycin/nitrofurantoin for UTIs. Beta-lactam/beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam) are unreliable despite in vitro susceptibility. ### Mnemonic: **ESBL** — **E**. coli and Klebsiella, **S**usceptible to carbapenems, **B**eta-lactamase inhibitor-sensitive, **L**arge plasmid-mediated spread. [cite: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed., Ch. 18; Clinical Microbiology Reviews 2010 Vol 23(2); Harrison's Principles of Internal Medicine, 21st ed.]